


Date of Deposit: April 16, 2009



Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	09/830,400
Filing Date	July 20, 2001
First Named Inventor	Nadler
Group Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	20363-015 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A4	5,399,346	03/21/95	Anderson et al.	424	93.21	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Yes	No
	B6	WO 98/04582	LUDWIG INSTITUTE FOR CANCER RESEARCH	02/05/98		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C5	Alexander et al., "Derivation of HLA-A11/K ^b transgenic Mice" <i>J. Immunol.</i> , 159:4753-4761 (1997)
	C6	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes", <i>Science</i> , 274:94-96 (1996)
	C7	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", <i>Nuc. Acids Res.</i> , 25(17):3389-3402 (1997)
	C8	Anderson et al., "Intracellular Transport of Class I MHC Molecules in Antigen Processing Mutant Cell Lines", <i>J. Immunol.</i> , 151(7):3407-3419 (1993)
	C9	Anderson, W.F., "Prospects for Human Gene Therapy", <i>Science</i> , 226:401-409 (1984)
	C10	Aruga et al., "Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells", <i>Cancer Immunol. Immunother.</i> , 41:317-324 (1995)
	C11	Ashley et al., "Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors", <i>J. Exp. Med.</i> , 186(7):1177-1182 (1997)
	C12	Blomer et al., "Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector", <i>J. Virol.</i> , 71(9):6641-6649 (1997)
	C13	Boczkowski et al., "Dendritic Cells Pulsed with RNA are Potent Antigen-presenting Cells In Vitro and In Vivo", <i>J. Exp. Med.</i> , 184:465-472 (1996)
	C14	Bohlen et al., "Differentiation of cytotoxicity using target cells labeled with europium and samarium by electroporation", <i>J. Immunol. Meth.</i> , 173:55-62 (1994)

C15	Boon et al., "Tumor antigens recognized by T lymphocytes", <i>Ann. Rev. Immunol.</i> , 12:337-365 (1994)
C16	Brigham et al., "Rapid Communication: <i>In vivo</i> Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle", <i>Am. J. Med. Sci.</i> , 298(4):278-281 (1989)
C17	Broccoli et al., "Telomerase activity in normal and malignant hematopoietic cells", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 92:9082-9086 (1995)
C18	Brodie et al., " <i>In vivo</i> migration and function of transferred HIV-1-specific cytotoxic T cells", <i>Nat. Med.</i> , 5(1):34-41 (1999)
C19	Brossart et al., "Identification of HLA-A2_Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <i>Blood</i> , 93:4309-4317 (1999)
C20	Brusic et al., "MHCPEP, a database of MHC-binding peptides: update 1997", <i>Nuc. Acids Res.</i> , 26(1):368-371 (1998)
C21	Brusic et al., "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network", <i>Bioinformatics</i> , 14(2):121-130 (1998)
C22	Bryan et al., "Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines", <i>Nat. Med.</i> , 3(11):1271-1274 (1997)
C23	Buchovich et al., "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells", <i>Mol. Bio. Cell</i> , 7:1443-1454 (1996)
C24	Busch et al., "MHC Class I/Peptide Stability: Implications for Immunodominance, In Vitro Proliferation, and Diversity of Responding CTL", <i>J. Immunol.</i> , 160:4441-4448 (1998)
C25	Callan et al., "Direct Visualization of Antigen-specific CD8 ⁺ T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo", <i>J. Exp. Med.</i> , 187:1395-1402 (1998)
C26	Cayouette et al., "Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (<i>rd</i>) Mouse", <i>Hum. Gene Ther.</i> , 8:423-430 (1997)
C27	Cornetta et al., "Gene Transfer into Primates and Prospects for Gene Therapy in Humans", <i>Nucl. Acid Res. Mol. Biol.</i> , 36:311-322 (1987)
C28	Cornette et al., "Periodic variation in side-chain polarities of T-cell antigenic peptides correlates with their structure and activity", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 92:8368-8372 (1995)
C29	Counter et al., "Stabilization of Short Telomeres and Telomerase Activity Accompany Immortalization of Epstein-Barr Virus-Transformed Human B Lymphocytes", <i>J. Virol.</i> , 68:3410-3414 (1994)
C30	Counter et al., "Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase", <i>Oncogene</i> , 16:1217-1222 (1998)
C31	De Groot et al., "Prediction of Protein Conformational Freedom From Distance Constraints", <i>Proteins: Struct. Funct. Genet.</i> , 29:240-251 (1997)
C32	DeLisi et al., "T-cell antigenic sites tend to be amphipathic structures", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 82:7048-7052 (1985)
C33	Dunbar et al., "Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood", <i>Curr. Biol.</i> , 8:413-416 (1998)
C34	Eglitis et al., "Retroviral vectors for introduction of genes into mammalian cells", <i>BioTechniques</i> , 6(7):608-614 (1988)
C35	Engelhard, "Structure of peptides associated with class I and class II MHC molecules", <i>Ann. Rev. Immunol.</i> , 12:181-207 (1994)

C36	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human <i>c-myc</i> Proto-Oncogene Product", <i>Mol. Cell Biol.</i> , 5(12):3610-3616 (1985)
C37	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 84:7413 -7417(1987)
C38	Feltkamp et al., "Efficient MHC Class I-Peptide Binding is Required but does not Ensure MHC Class I-Restricted Immunogenicity", <i>Mol. Immunol.</i> , 31(18):1391-1401 (1994)
C39	Feng et al., "The RNA Component of Human Telomerase", <i>Science</i> , 269:1236-1241 (1995)
C40	Ferrari et al., "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen", <i>J. Clin. Invest.</i> , 88:214-222 (1991)
C41	Friedman, T., "Progress Toward Human Gene Therapy", <i>Science</i> , 244:1275-1281 (1989)
C42	Gallimore et al., "A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells", <i>Eur. J. Immunol.</i> , 28:3301-3311 (1998)
C43	Gallimore et al., "Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides", <i>J. Exp. Med.</i> , 187:1647-1657 (1998)
C44	Genbank Accession No. AF018167.1, August 28, 1997, 4 pages.
C45	Gulukota et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules", <i>J. Mol. Biol.</i> , 267:1258-1267 (1997)
C46	Gulukota et al., "HLA allele selection for designing peptide vaccines", <i>Genetic Analysis: Biomol. Engineering</i> , 13:81-86 (1996)
C47	Hammer et al., "New methods to predict HMC-binding sequences within protein antigens", <i>Curr. Opin. Immunol.</i> , 7:263-269 (1995)
C48	Hammer et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning", <i>J. Exp. Med.</i> , 180:2353-2358 (1994)
C49	Harle-Bachor et al., "Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes", <i>Proc. Natl. Acad. Sci. USA</i> , 93:6476-6481(1996)
C50	Herr et al., "Detection and quantification of blood-derived CD8 ⁺ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens", <i>J. Immunol. Meth.</i> , 191:131-142 (1996)
C51	Herr et al., "The use of computer-assisted video image analysis for the quantification of CD8 ⁺ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens", <i>J. Immunol. Meth.</i> , 203:141-152 (1997)
C52	Hiyama et al., "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells", <i>J. Immunol.</i> , 155:3711-3715 (1995)
C53	Hsu et al., "Tumor-Specific Idiotypic Vaccines in the Treatment of Patients With B-Cell Lymphoma --- Long-Term Results of a Clinical Trial", <i>Blood</i> , 89:3129-3135 (1997)
C54	Igarashi et al., "Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor", <i>Blood</i> , 89:1299-1307 (1997)
C55	Jager et al., "Immunoselection In Vivo: Independent Loss of MHC Class I and Melanocyte Differentiation Antigen Expression in Metastatic Melanoma", <i>Int. J. Cancer</i> , 71:142-147 (1997)
C56	Johnson, L.G., "Gene Therapy for Cystic Fibrosis", <i>Chest</i> , 107:77S-83S (1995)
C57	Kammer et al., "Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition", <i>J. Exp. Med.</i> , 190(2):169-176 (1999)

C58	Kido et al., "Use of a retroviral vector with an internal opsin promoter to direct gene expression to retinal photoreceptor cells", <i>Curr. Eye Res.</i> , 15:833-844 (1996)
C59	Kim et al., "Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)", <i>Nuc. Acids Res.</i> , 25(13):2595-2597 (1997)
C60	Kiyono et al., "Both Rb/p16 ^{INK4a} inactivation and telomerase activity are required to immortalize human epithelial cells", <i>Nature</i> , 396:84-88 (1998)
C61	Klingelhutz et al., "Restoration of Telomeres in Human Papillomavirus-Immortalized Human Anogenital Epithelial Cells", <i>Mol. Cell. Biol.</i> , 14(2):961-969 (1994)
C62	Klingelhutz et al., "Telomerase activation by the E6 gene product of human papillomavirus type 16", <i>Nature</i> , 380:79-82 (1996)
C63	Kolquist et al., "Expression of <i>TERT</i> in early premalignant lesions and a subset of cells in normal tissues", <i>Nat. Genet.</i> , 19:182-186 (1998)
C64	Kubo et al., "Definition of specific peptide motifs for four major HLA-A alleles", <i>J. Immunol.</i> , 152:3913-3924 (1994)
C65	Kuska, B., "Cancer Genome Anatomy Project Set for Take-off", <i>J. Nat'l. Cancer Inst.</i> , 88(24):1801-1803 (1996)
C66	Larvol et al., "In silico drug discovery: Tools for bridging the NCE gap", <i>Nat. Biotechnol.</i> , 16(Suppl.):33-34 (1998)
C67	Le Gal La Salle et al., "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain", <i>Science</i> , 259:988-990 (1993)
C68	Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients", <i>Nat. Med.</i> , 5(6):677-685 (1999)
C69	Madden, D.R., "The three-dimensional structure of peptide-MHC complexes", <i>Ann. Rev. Immunol.</i> , 13:587-622 (1995)
C70	Malakoff, D., "Biocomputing: NIH Urged to Fund Centers to Merge Computing and Biology", <i>Science</i> , 284(5421):1742 (1999)
C71	Mammi et al., Scientific Proceedings 89 th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 28-April 1, 1998, Abstract #62
C72	Man et al., "Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice", <i>Int. Immunol.</i> , 7(4):597-605 (1995)
C73	McMichael et al., "A New Look at T Cells", <i>J. Exp. Med.</i> , 187(9):1367-1371 (1998)
C74	Meyerson et al., "hEST2, The Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization", <i>Cell</i> , 90:785-795 (1997)
C75	Miller et al., "Improved Retroviral Vectors for Gene Transfer and Expression", <i>Biotech.</i> , 7(9):980-990 (1989)
C76	Miller, A.D., "Retrovirus Packaging Cells", <i>Human Gene Ther.</i> , 1:5-14 (1990)
C77	Miyoshi et al., "Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 94:10319-10323 (1997)
C78	Moen, R.C., "Directions in Gene Therapy", <i>Blood Cells</i> , 17:407-416 (1991)
C79	Molldrem et al., "Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells", <i>Blood</i> , 88:2450-2457 (1996)

C80	Morgenstern et al., "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line", <i>Nucl. Acids Res.</i> , 18(12):3587-3596 (1990)
C81	Nair et al., "Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells", <i>Nature Med.</i> , 6(8):1011-1017 (2000)
C82	Nakamura et al., "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human", <i>Science</i> , 277:955-959 (1997)
C83	Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", <i>Science</i> , 272:263-267 (1996)
C84	Nijman et al., "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes", <i>Eur. J. Immunol.</i> , 23:1215-1219 (1993)
C85	Norrback et al., "Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas", <i>Blood</i> , 88:222-229 (1996)
C86	Ono et al., "Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells", <i>Neurosci. Lett.</i> , 117:259-263 (1990)
C87	Pamer et al., "Mechanisms of MHC Class I-restricted antigen processing", <i>Ann. Rev. Immunol.</i> , 16:323-358 (1998)
C88	Parker et al., "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction", <i>Immunol. Res.</i> , 14:34-57 (1995)
C89	Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains", <i>J. Immunol.</i> , 152:163-175 (1994)
C90	Paul, W.E., "Antigen Processing and Presentation", in <i>Fundamental Immunol.</i> , 3 rd Edition, Chapter 17, Raven Press, Ltd., New York, NY, pages 629, 641-643 (1993)
C91	Porgador et al., "Localization, Quantitation, and In Situ Detection of Specific Peptide-MHC Class I Complexes Using a Monoclonal Antibody", <i>Immunity</i> , 6:715-726 (1997)
C92	Prowse et al., "Developmental and tissue-specific of mouse telomerase and telomere length", <i>Proc. Natl. Acad. Sci. USA</i> , 92:4818-4822 (1995)
C93	Rammensee et al., "MHC ligands and peptide motifs: first listing", <i>Immunogenetics</i> , 41:178-228 (1995)
C94	Rammensee et al., "Peptides naturally presented by MHC class I molecules", <i>Ann. Rev. Immunol.</i> , 11:213-244 (1993)
C95	Riddell et al., "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients", <i>Nat. Med.</i> , 2(2):216-223 (1996)
C96	Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides", <i>Ann Rev Immunol.</i> , 17:739-779 (1999)
C97	Romero et al., "Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes", <i>J. Exp. Med.</i> , 188(9):1641-1650 (1998)
C98	Rosenberg et al., "Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction", <i>N. Engl. J. Med.</i> , 323:570-578 (1990)
C99	Rosenberg, S.A., "A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens", <i>Immunity</i> , 10:281-287 (1999)

C100	Rosenberg, S.A., "Cancer vaccines based on the identification of genes encoding cancer regression antigens", <i>Immunol. Today</i> , 18(1):175-182 (1997)
C101	Rosenberg et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", <i>Nat. Med.</i> , 4(3):321-327 (1998)
C102	Rothbard et al., "Interactions between immunogenic peptides and MHC proteins", <i>Ann. Rev. Immunol.</i> , 9:527-565 (1991)
C103	Ruppert et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules", <i>Cell</i> , 74:929-937 (1993)
C104	Sahin et al., "Serological identification of human tumor antigens", <i>Curr. Opin. Immunol.</i> , 9:709-716 (1997)
C105	Salter et al., "Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid", <i>EMBO J.</i> , 5(5):943-949 (1986)
C106	Sarma et al., "Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo", <i>J. Exp. Med.</i> , 189(5):811-820 (1999)
C107	Savage et al., "A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response", <i>Immunity</i> , 10:485-492 (1999)
C108	Scheibenbogen et al., "A Sensitive ELISPOT Assay for Detection of CD8 ⁺ T Lymphocytes Specific for HLA Class I-binding Peptide Epitopes Derived from Influenza Proteins in the Blood of Healthy Donors and Melanoma Patients", <i>Clin. Cancer Res.</i> , 3:221-226 (1997)
C109	Scheibenbogen et al., "Analysis of the TCell Response to Tumor and Viral Peptide Antigens by an IFN γ -ELISPOT Assay", <i>Int. J. Cancer</i> , 71:932-936 (1997)
C110	Schmittel et al., "Evaluation of the interferon- γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood", <i>J. Immunol. Meth.</i> , 210:167-174 (1997)
C111	Schonbach et al., "Fine Tuning of Peptide Binding to HLA-B*3501 Molecules by Nonanchor Residues", <i>J. Immunol.</i> , 154:5951-5958 (1995)
C112	Schultze et al., "Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by t Cell Signals CD40 Ligand, Interferon γ , and IL-10: Role of B Cells in the Maintenance of T Cell Responses", <i>J. Exp. Med.</i> , 89(1):1-11 (1999)
C113	Schumacher et al., "Direct Binding of Peptide to Empty MHC Class I Molecules on Intact Cells and In Vitro", <i>Cell</i> , 62:563-567 (1990)
C114	Sette et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes", <i>J. Immunol.</i> , 153:5586-5592 (1994)
C115	Sharp, D., "Gene Therapy", <i>Lancet</i> , 337:1277-1278 (1991)
C116	Sidney et al., "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs", <i>Immunol. Today</i> , 17(6):261-266 (1996)
C117	Stöppler et al., "The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length", <i>J. Biol. Chem.</i> , 272(20):13332-13337 (1997)
C118	Straubinger et al., "Liposomes as Carriers for Intracellular Delivery of Nucleic Acids", <i>Meth. Enz.</i> , 101:512-527 (1983)
C119	Tolstoshev et al., "Gene expression using retroviral vectors", <i>Curr. Opin. Biotech.</i> , 1:55-61 (1990)
C120	Tompkins et al., "A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins", <i>J. Immunol. Meth.</i> , 163:209-216 (1993)

C121	Townsend et al., "Assembly of MHC Class I Molecules Analyzed In Vitro", <i>Cell</i> , 62:285-295 (1990)
C122	Valmori et al., "An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer", <i>Cancer Res.</i> , 59:2167-2173 (1999)
C123	Van den Eynde et al., "T cell defined tumor antigens", <i>Curr. Opin. Immunol.</i> , 9:684-693 (1997)
C124	Van der Burg et al., "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability", <i>J. Immunol.</i> , 156:3308-3314 (1996)
C125	Van Pel et al., "Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes", <i>Immunol. Rev.</i> , 145:229-250 (1995)
C126	Weng et al., "Telomere lengthening and telomerase activation during human B cell differentiation", <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 94:10827-10832 (1997)
C127	Wentworth et al., "Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome", <i>Int. Immunol.</i> , 8(5):651-659 (1996)
C128	Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo", <i>Science</i> , 247:1465-1468 (1990)
C129	Wu et al., "Receptor-mediated Gene Delivery and Expression in Vivo" <i>J. Biol. Chem.</i> , 263(29):14621-14624 (1988)
C130	Wu et al., "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo", <i>J. Biol. Chem.</i> , 264(29):16985-16987 (1989)
C131	Yasumoto et al., "Telomerase activity in normal human epithelial cells", <i>Oncogene</i> , 13:433-439 (1996)
C132	Yee et al., "Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers", <i>J. Immunol.</i> , 162:2227-2234 (1999)
C133	Letter dated April 29, 2008, enclosing Form 1037, Re: European SApplication No. 99956777.9-2402/1126872, 5 pages (2008)
C134	Priority Document for Patent Application No. 19983141, "Antigenic Peptides", Gaudernack et al., Norway, 40 pages (1999)
C135	Priority Document dated April 12, 1999, for Application No. 60/112,006, filed March 31, 1998, PCT Application No. PCT/US99/06898, 29 pages.
C136	Notice of Opposition to European Patent No. 1 126 872, in the name of Dana-Farber Cancer Institute, Inc. & Whitehead Institute for Biomedical Research, by Geron Corporation, dated September 13, 2007, 22 pages.
C137	Notice of Opposition to European Patent No. 1126872 in the name of Dana-Farber Cancer Institute, Inc. & Whitehead Institute for Biomedical Research, by Merck & Co., Inc., dated September 13, 2007, 13 pages.

* By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patents A4 is not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4587454v.1